Physician profile
Darren Smeal
NPI 1356382493
$6,314.38
in general payments reported to CMS, 2019-2025
40 companies · $989 in 2025
The $989 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,112 · 2020: $716 · 2021: $927 · 2022: $980 · 2023: $764 · 2024: $827 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,580.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $826.65 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $634.54 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $521.44 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $460.05 | 2019-2025 | Xarelto, Spravato |
| Pfizer INC. | $454.29 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $449.88 | 2019-2023 | |
| Abbott Laboratories | $290.55 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Abbvie INC. | $286.50 | 2021-2025 | Vraylar |
| Amarin Pharma, INC. | $195.71 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $178.44 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.91 | 2021-2023 | Xifaxan, Trulance |
| Exact Sciences Corporation | $165.13 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $151.68 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $141.60 | 2020-2025 | Mounjaro |
| Phathom Pharmaceuticals, INC. | $140.03 | 2024-2025 | Voquezna |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Smeal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.